Dr Richard Barker, Director General of the ABPI said: “In this challenging economic climate, we are pleased the Government has recognised the importance of maintaining ring fenced public funding of £4.6 billion annually for science.”
“Scientific research is critical to securing future economic growth and the UK can harness the rich opportunities offered by medical science for the benefit of patients and society. It will be essential for the forthcoming Growth White Paper to set out a clear strategy for the UK to maintain its comparative advantage in the life sciences.”
“The Office for Life Sciences and implementation of the actions agreed in the Life Science Blueprint are also critically important in helping to address the industrial challenges currently facing the UK.”
“The ABPI will continue to work closely with its colleagues at BIA, BIVDA, ABHI and the Minister for Health, Earl Howe and the Minister for Universities and Science, David Willetts MP to ensure that the Office for Life Sciences can deliver the best possible environment to support UK life sciences and the development of new treatments for patients.”
“The ABPI welcomes the continued commitment from the Coalition Government to increase funding to the NHS for every year of this Parliament and increased spending on health research from the Department of Health.”
“The Government’s commitment to the Cancer Drugs Fund will mean that more cancer patients will be able to get access to the latest available medicines than before. The UK currently ranks amongst the lowest in Europe in the uptake of innovative medicines, despite having amongst the lowest prices. As the NHS faces the challenge of achieving £20 billion annual efficiency savings, innovative new medicines will be an important part of the solution to reduce the long term burden of disease, and so deliver cost-effective care.”
For further information, please contact the ABPI press office: 020 7747 1410.